 NEW YORK, March 12, 2021 PRNewswire -- Pomerantz LLP announces that a class action lawsuit has been filed against Immunovant, Inc. fka Health Sciences Acquisitions Corporation HSAC, Immunovant, or the Company NASDAQ: IMVT; HSACU; HSAC; and HSACW and certain of its officers. The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 21-cv-00918, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Immunovant securities between October 2, 2019 and February 1, 2021, both dates inclusive the Class Period, seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10b and 20a of the Securities Exchange Act of 1934 the Exchange Act and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials. 